SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spacecoin is a satellite-based decentralized internet network that aims to provide reliable, permissionless connectivity across the globe. It is building a constellation of blockchain-enabled small satellites in low-Earth orbit to transmit data back to the Earth without heavily relying on traditional internet infrastructure such as cell towers and fiber-optic cables. The goal is to provide a reliable lifeline connection for the 2.6 billion people globally who have never connected to the Internet and an additional 3.5 billion who live with restricted access.  Spacecoin plans to offer services in its target countries of Nigeria, Indonesia, and India for as low as $1-2 per month per user. The network works as an open system where anyone can add satellites. The first satellite launched in December 2024, with three more planned for October 2025.

Spacelens

The community is actively discussing the highly anticipated SpaceX IPO and its broader impact on the aerospace and satellite infrastructure sectors. Investors are debating the project's long-term potential within the Web3 space, while closely monitoring how partnerships and government space technology initiatives might influence related assets.

Samsara, Inc. develops internet connected sensor systems. It combines plug-and-play sensors, wireless connectivity, and cloud-hosted software integrated for deployment. The company was founded by John Bicket and Sanjit Biswas in 2015 and is headquartered in San Francisco, CA.

Samsara Inc - Ordinary Shares - Class A

Samsara Inc

Samsara Inc. (IOT) is currently drawing significant investor interest as the market positions itself for the upcoming quarterly earnings report. The community is actively debating the stock's growth potential and valuation, with many traders closely watching technical resistance levels as they balance excitement over the company's AI-driven industrial platform against broader software sector volatility.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as investors react to the company's Q4 financial results, which included a wider-than-expected loss and weaker-than-anticipated 2026 revenue guidance. The stock is further pressured by the surprise announcement that co-founders Ugur Sahin and zlem Treci will depart the company by the end of the year to launch an independent mRNA-focused startup, raising questions about future leadership and strategic direction.

Funko, Inc. engages in designing, sourcing, and distributing licensed pop culture products. Its product lines include media and entertainment content, which refer to movies, TV shows, video games, music, and sports. It operates through the United States, Europe, and Other International geographic segments. The company was founded in 1998 and is headquartered in Everett, WA.

Funko Inc - Ordinary Shares - Class A

Funko Inc. is seeing heightened market attention as investors speculate on potential buyout interest and a broader turnaround strategy, supported by bullish sentiment around recent product launches and debt reduction efforts. The community is actively discussing the stock's potential for a short squeeze, while carefully monitoring management's ability to maintain margins and navigate broader economic pressures.

KAIO provides institutional-grade real-world asset (RWA) tokenization infrastructure that seamlessly connects traditional investment funds with digital capital markets. Through its purpose-built protocol, KAIO enables leading global asset managers to issue and distribute regulated tokenized funds across multiple high-performance blockchain networks — including Ethereum, Sei, Hedera, Solana, Aptos, and others — significantly expanding global access to institutional-quality real-world asset strategies for qualified investors.   By tokenizing feeder structures and shares in flagship funds, KAIO brings onchain access to proven strategies such as the BlackRock ICS US Dollar Liquidity Fund (one of the world’s largest institutional money market funds), the Brevan Howard Master Fund, Hamilton Lane’s Senior Credit Opportunities Fund (SCOPE) via the HL SCOPE Access Fund, and Laser Digital’s Laser Carry Fund (LCF), among others. These tokenized vehicles deliver secure, compliant exposure to money market, macro, private credit, and alternative strategies while unlocking new levels of programmability, composability, and 24/7 liquidity in DeFi environments.

KAIO

KAIO is trending as market participants speculate on a potential price reversal driven by heavy accumulation and its positioning within the real-world assets sector. While some traders are bullish on a breakout and increased accessibility to assets, others remain cautious due to recent downward volatility and inconsistent performance since launch.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class A

Fox Corporation

Fox Corporation is currently drawing market attention as investors weigh the company's defensive strength and live sports strategy against broader cord-cutting pressures. The community remains focused on how the media giant balances traditional broadcast dominance with its aggressive push into digital streaming and sports-betting partnerships.

XDC Network is an enterprise-ready hybrid Blockchain technology company optimized for international trade and finance. The XDC Network is powered by the native coin called XDC. The XDC protocol is architected to support smart contracts, 2000TPS, 2seconds transaction time, KYC to Masternodes (Validator Nodes). The XDC Chain (XinFin Digital Contract) uses XinFin Delegated Proof of Stake (XDPoS), with the intending to create a ‘highly-scalable, secure, permission, and commercial grade’ blockchain network. XinFin mainnet token XDC and also creates an opportunity to utilize the XinFin’s real-world use-cases such as TradeFinex.org, helps small and medium businesses or institutions originate their own financial requirements in a digital, fully structured manner so that they can distribute it to the bank or non-bank funders themselves using a common distribution standard.

XinFin Network

The XinFin Network community is actively debating the token's long-term utility in global trade finance, with many users focused on its potential as a core asset for ISO 20022-compliant cross-border payments. While some investors express frustration over sluggish price action and limited exchange availability, others continue to accumulate on dips, citing institutional partnerships and RWA tokenization as the primary catalysts for a future breakout.

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Dyne Therapeutics Inc

Dyne Therapeutics is trending as investors react to positive clinical data from its ACHIEVE and DELIVER trials, which demonstrate the potential efficacy of its proprietary FORCE platform in treating rare neuromuscular diseases. The community is actively debating the stock's valuation, potential acquisition interest, and the impact of recent clinical milestones on its long-term competitive positioning within the biotech sector.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is generating intense community debate as investors weigh the project's low circulating supply and potential DeFi utility against ongoing concerns regarding market manipulation and lagging performance compared to peers. Bulls are actively accumulating on dips in anticipation of a supply-side squeeze and long-term sector recovery, while skeptics remain cautious about the protocol's fundamental direction and competitive standing in the evolving DeFi landscape.

Unleash Jugs

JUGS is gaining significant community attention as a new meme-focused cryptocurrency, with participants highlighting its low holder count and high concentration of tokens among top wallets as catalysts for potential volatility. Supporters are actively discussing the coin's momentum and long-term price aspirations, frequently linking its trend to other emerging assets within the speculative crypto space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy

AZN's Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.

Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer 

RHHBY wins FDA approval for Tecentriq label expansion as a ctDNA-guided adjuvant therapy for bladder cancer patients at high risk of recurrence.

Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year

KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.

CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised

CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.

ESPR Stock Surges 44% in a Month: Here's What You Need to Know

Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.

Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil

ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1

ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.

Dr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock Down

RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.

Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease

AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus

Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

AMRN
Amarin Corp - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest AMRN News

AMRNAmarin Corp - ADR